Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cesar A Santa-Maria

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
NPJ Breast Cancer|December 30, 2022
A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013Foluso O Ademuyiwa, Feng Gao, Cherease R Street, et al.
Nature Medicine|October 19, 2023
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trialJason J Luke, Manish R Patel, George R Blumenschein, et al.
Cancer Research Communications|April 30, 2024
Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast CancerElizabeth C Wescott, Xiaopeng Sun, Paula Gonzalez-Ericsson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 10, 2025
NCCN Guidelines® Insights: Breast Cancer, Version 5.2025William J Gradishar, Meena S Moran, Jame Abraham, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 9, 2026
Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In OncologyWilliam J Gradishar, Meena S Moran, Jame Abraham, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
NPJ Breast Cancer|December 30, 2022
A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013Foluso O Ademuyiwa, Feng Gao, Cherease R Street, et al.
Nature Medicine|October 19, 2023
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trialJason J Luke, Manish R Patel, George R Blumenschein, et al.
Cancer Research Communications|April 30, 2024
Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast CancerElizabeth C Wescott, Xiaopeng Sun, Paula Gonzalez-Ericsson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 10, 2025
NCCN Guidelines® Insights: Breast Cancer, Version 5.2025William J Gradishar, Meena S Moran, Jame Abraham, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 9, 2026
Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In OncologyWilliam J Gradishar, Meena S Moran, Jame Abraham, et al.
Pageof 6